Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains?

Assembly Biosciences (ASMB) shares ended the last trading session 9.8% higher at $24.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.4% loss over the past four weeks.Assembly Biosciences’ sudden stock price gain can be attributed to the positive investor mindset regarding the potential of the company’s innovative pipeline, comprising four candidates being developed in separate early-stage studies for the treatment of recurrent genital herpes, Hepatitis B and Hepatitis D.This biotech drug developer is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of +66.9%. Revenues are expected to be $10.2 million, up 49.1% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Assembly Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASMB going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Assembly Biosciences is part of the Zacks Medical - Generic Drugs industry. Doctor Reddy's (RDY), another stock in the same industry, closed the last trading session 0.3% higher at $14.87. RDY has returned 2.8% in the past month.For Doctor Reddy's, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.18. This represents a change of +350% from what the company reported a year ago. Doctor Reddy's currently has a Zacks Rank of #3 (Hold).Free Report: 3 Software Stocks Poised to SkyrocketSoftware stocks are poised to catapult higher in the coming months (and years) thanks to several factors, especially the explosive growth of AI. Zacks' urgent report reveals 3 top software stocks to own right now.Access the report free today >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Assembly Biosciences, Inc. (ASMB): Free Stock Analysis Report Dr. Reddy's Laboratories Ltd (RDY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks